118.21
-1.43%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Haemonetics
From its filings with the US Securities and Exchange Commission
Haemonetics is based in Boston, Massachusetts and is incorporated in Massachusetts. Its shares trade on NYSE under the ticker HAE. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 28 March 2026, it reported revenue of $1.33bn and net income of $97.3m. At that date it held total assets of $2.40bn and shareholders' equity of $796.3m.
We believe that Plasma and Hospital have the greatest growth potential and are well positioned to drive long-term value. Blood Center operates in more challenging markets, and we have sharpened our focus accordingly on targeted opportunities – particularly in plasma and platelets – while ensuring continued alignment of this business with the Company’s broader strategic objectives.
The following describes our principal products in each of our segments. Availability of products may vary from one country or region to another as a result of specific local regulatory approval or clearance requirements. Applicable laws may restrict the sale, distribution or use of these products to, by, or on the order of a licensed healthcare practitioner.
Our Plasma business offers automated plasma collection systems, donor management software and supporting software solutions that enable optimization of the yield, efficiency, quality and overall donor experience at plasma collection centers. We continue to invest in technology that lowers the overall cost to collect plasma while maintaining high standards of quality and safety.
Quoted from its 10-K, filed 20 May 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 17 Oct 1979
- Employees
- 3,009
- Website
- haemonetics.com ↗
- Head office
- 125 SUMMER STREET, BOSTON, MA, 02110
- Incorporated in
- MA
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Ms. Ellen ZaneIndependent Chairman of the Board$449,954
- Mr. Christopher SimonPresident, Chief Executive Officer, Director, since 2016$10.7m
- Mr. James D'AreccaExecutive Vice President, Chief Financial Officer$3.0m
- Dr. Frank ChanChief Operating Officer, Executive Vice President
- Ms. Laurie MillerChief Human Resources Officer, Senior Vice President
- Ms. Michelle BasilExecutive Vice President, General Counsel$2.8m
- Mr. Roy GalvinExecutive Vice President, Chief Commercial Officer$2.2m
- Mr. Josep LlorensExecutive Vice President - Global Manufacturing and Supply Chain$2.4m
- Ms. Olga GuyetteVice President, Investor Relations & Treasury
- Mr. Robert AbernathyIndependent Director$294,954
- Ms. Diane BryantIndependent Director$279,954
- Mr. Michael CoyleIndependent Director$282,954
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 50
- Environment
- 40
- Social
- 65
- Governance
- 46
- Direct emissions (scope 1)
- 5,701.85 t
- Energy emissions (scope 2)
- 19,269.47 t
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Haemonetics Corp has several strengths that contribute to its position in the market:
Weaknesses
- Despite its strengths, Haemonetics Corp also faces certain weaknesses:
Opportunities
- There are several opportunities that Haemonetics Corp can capitalize on:
Threats
- Haemonetics Corp must also address certain threats that may impact its business:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.